189 related articles for article (PubMed ID: 36998031)
1. Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw.
Mu H; Pang Y; Liu L; Liu J; Liu C
Eur J Med Res; 2023 Mar; 28(1):140. PubMed ID: 36998031
[TBL] [Abstract][Full Text] [Related]
2. Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Movila A; Mawardi H; Nishimura K; Kiyama T; Egashira K; Kim JY; Villa A; Sasaki H; Woo SB; Kawai T
Biochem Biophys Res Commun; 2016 Nov; 480(1):42-47. PubMed ID: 27720716
[TBL] [Abstract][Full Text] [Related]
3. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
4. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
Sobczak-Jaskow H; Kochańska B; Drogoszewska B
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
[No Abstract] [Full Text] [Related]
5. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?
Giovannacci I; Meleti M; Manfredi M; Mortellaro C; Greco Lucchina A; Bonanini M; Vescovi P
J Craniofac Surg; 2016 May; 27(3):697-701. PubMed ID: 27092912
[TBL] [Abstract][Full Text] [Related]
6. Medication-Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium.
Yang G; Williams R; Wang L; Farhadfar N; Chen Y; Loiacono AT; Bian J; Holliday LS; Katz J; Gong Y
J Bone Miner Res; 2022 Dec; 37(12):2466-2471. PubMed ID: 36151778
[TBL] [Abstract][Full Text] [Related]
7. [The role of semaphorin 4D in the mechanism of bisphosphonate-related osteonecrosis of the jaw in rats].
Pan QT; Zang XL; Sun ZW; Pan MQ; Zhu XM; Li ZY
Shanghai Kou Qiang Yi Xue; 2022 Dec; 31(6):625-631. PubMed ID: 36970799
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
9. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
10. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
12. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
13. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
14. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
15. Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies.
Jiang A; Zhang Z; Qiu X; Guo Q
Arch Toxicol; 2024 Mar; 98(3):689-708. PubMed ID: 38155341
[TBL] [Abstract][Full Text] [Related]
16. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
Roato I; Mauceri R; Notaro V; Genova T; Fusco V; Mussano F
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175652
[TBL] [Abstract][Full Text] [Related]
17. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis.
Dos Santos Ferreira L; Abreu LG; Calderipe CB; Martins MD; Schuch LF; Vasconcelos ACU
Osteoporos Int; 2021 Dec; 32(12):2449-2459. PubMed ID: 34331067
[TBL] [Abstract][Full Text] [Related]
18. [Progress on medication-related osteonecrosis of the jaw].
Wang QZ; Liu JY; Pan J
Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354
[TBL] [Abstract][Full Text] [Related]
19. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review.
Aljohani S; Fliefel R; Ihbe J; Kühnisch J; Ehrenfeld M; Otto S
J Craniomaxillofac Surg; 2017 Sep; 45(9):1493-1502. PubMed ID: 28687467
[TBL] [Abstract][Full Text] [Related]
20. Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users.
El-Ma'aita A; Da'as N; Al-Hattab M; Hassona Y; Al-Rabab'ah M; Al-Kayed MA
J Int Med Res; 2020 Sep; 48(9):300060520955066. PubMed ID: 32924697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
